Publications by authors named "Lorinda Simms"

Claim this Profile
I
Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm).
Robert Paine, Robert Chasse, E Scott Halstead, Jay Nfonoyim, David J Park, Lorinda Simms

Mil Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Lorinda Simms

J Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannova, Gyorgy Bodoky, Lorinda Simms

Lancet Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WITHDRAWN: Anti-tuberculous therapy for maintenance of remission in Crohn's disease.
Mark Borgaonkar, Don MacIntosh, John Fardy, Lorinda Simms

Cochrane Database Syst Rev· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
John R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, Nicole McCarthy, Dmitriy Krasnozhon, Lorinda Simms

J Clin Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Edward S Kim, Marcus Neubauer, Allen Cohn, Lee Schwartzberg, Lawrence Garbo, Lorinda Simms

Lancet Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In response.
Helen Barraclough, Lorinda Simms, Ramaswamy Govindan

J Thorac Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biostatistics primer: what a clinician ought to know--prognostic and predictive factors.
Lorinda Simms, Helen Barraclough, Ramaswamy Govindan

J Thorac Oncol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biostatistics primer: what a clinician ought to know: hazard ratios.
Helen Barraclough, Lorinda Simms, Ramaswamy Govindan

J Thorac Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Giorgio Scagliotti, Thomas Brodowicz, Frances A Shepherd, Christoph Zielinski, Johan Vansteenkiste, Lorinda Simms

J Thorac Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Silvia Novello, Francisco Luis Pimentel, Jean-Yves Douillard, Mary O'Brien, Joachim von Pawel, Lorinda Simms

J Thorac Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Chih-Hsin Yang, Lorinda Simms, Keunchil Park, Jin Soo Lee, Giorgio Scagliotti

J Thorac Oncol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
Axel-R Hanauske, Herlinde Dumez, Martine Piccart, Emine Yilmaz, Tobias Graefe, Lorinda Simms

Invest New Drugs· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Giorgio Scagliotti, Nasser Hanna, Frank Fossella, Katherine Sugarman, Johannes Blatter, Lorinda Simms

Oncologist· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review.
Fred R Hirsch, Anna Spreafico, Silvia Novello, Mary Dugan Wood, Lorinda Simms

J Thorac Oncol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
Kathy S Albain, Shona M Nag, German Calderillo-Ruiz, Johann P Jordaan, Antonio C Llombart, Lorinda Simms

J Clin Oncol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Lorinda Simms

J Clin Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer.
Robert Paridaens, Luc Dirix, Herlinde Dumez, Annemie Prové, Hans Wildiers, Lorinda Simms

Clin Breast Cancer· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
Antonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, Rodica M Anghel, Alexandra E Eniu, Lorinda Simms

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, Margit Gneist, Filip Janku, Lorinda Simms

Clin Cancer Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
Alain C Mita, Christopher J Sweeney, Sharyn D Baker, Andrew Goetz, Lisa A Hammond, Lorinda Simms

J Clin Oncol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori.
Sander Veldhuyzen van Zanten, Naoki Chiba, Alan Barkun, Carlo Fallone, Alain Farley, Lorinda Simms

Can J Gastroenterol· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized survey of the preference of gastroenterologists for a Cochrane review versus a traditional narrative review.
John W D McDonald, Jeffrey Mahon, Kelly Zarnke, Brian Feagan, Lorinda Simms

Can J Gastroenterol· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis